These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 32067509)

  • 1. Combination therapy with oncolytic viruses and immune checkpoint inhibitors.
    Chiu M; Armstrong EJL; Jennings V; Foo S; Crespo-Rodriguez E; Bozhanova G; Patin EC; McLaughlin M; Mansfield D; Baker G; Grove L; Pedersen M; Kyula J; Roulstone V; Wilkins A; McDonald F; Harrington K; Melcher A
    Expert Opin Biol Ther; 2020 Jun; 20(6):635-652. PubMed ID: 32067509
    [No Abstract]   [Full Text] [Related]  

  • 2. Oncolytic viruses combined with immune checkpoint therapy for colorectal cancer is a promising treatment option.
    Ren Y; Miao JM; Wang YY; Fan Z; Kong XB; Yang L; Cheng G
    Front Immunol; 2022; 13():961796. PubMed ID: 35911673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncolytic Viruses: Priming Time for Cancer Immunotherapy.
    Russell L; Peng KW; Russell SJ; Diaz RM
    BioDrugs; 2019 Oct; 33(5):485-501. PubMed ID: 31321623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolytic Viruses and Immune Checkpoint Inhibitors: Preclinical Developments to Clinical Trials.
    Hwang JK; Hong J; Yun CO
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33207653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination oncolytic virus, radiation therapy, and immune checkpoint inhibitor treatment in anti-PD-1-refractory cancer.
    Jhawar SR; Wang SJ; Thandoni A; Bommareddy PK; Newman JH; Marzo AL; Kuzel TM; Gupta V; Reiser J; Daniels P; Schiff D; Mitchell D; LeBoeuf NR; Simmons C; Goyal S; Lasfar A; Guevara-Patino JA; Haffty BG; Kaufman HL; Silk AW; Zloza A; Giurini EF
    J Immunother Cancer; 2023 Jul; 11(7):. PubMed ID: 37433716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disentangling Anti-Tumor Response of Immunotherapy Combinations: A Physiologically Based Framework for V937 Oncolytic Virus and Pembrolizumab.
    Sancho-Araiz A; Parra-Guillen ZP; Troconiz IF; Freshwater T
    Clin Pharmacol Ther; 2024 Nov; 116(5):1304-1313. PubMed ID: 39037559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combinatorial Approaches for Cancer Treatment Using Oncolytic Viruses: Projecting the Perspectives through Clinical Trials Outcomes.
    Malogolovkin A; Gasanov N; Egorov A; Weener M; Ivanov R; Karabelsky A
    Viruses; 2021 Jun; 13(7):. PubMed ID: 34209981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The oncolytic virus VT09X optimizes immune checkpoint therapy in low immunogenic melanoma.
    Zhu W; Lv J; Xie X; Tian C; Liu J; Zhou H; Sun C; Li J; Hu Z; Li X
    Immunol Lett; 2022 Jan; 241():15-22. PubMed ID: 34774916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment.
    Shi T; Song X; Wang Y; Liu F; Wei J
    Front Immunol; 2020; 11():683. PubMed ID: 32411132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy.
    Chen T; Ding X; Liao Q; Gao N; Chen Y; Zhao C; Zhang X; Xu J
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33504576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fueling immune checkpoint blockade with oncolytic viruses: Current paradigms and challenges ahead.
    Li SJ; Sun ZJ
    Cancer Lett; 2022 Dec; 550():215937. PubMed ID: 36206966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using oncolytic viruses to ignite the tumour immune microenvironment in bladder cancer.
    Li R; Zhang J; Gilbert SM; Conejo-Garcia J; Mulé JJ
    Nat Rev Urol; 2021 Sep; 18(9):543-555. PubMed ID: 34183833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of VSV-GP (BI 1831169) as monotherapy or combined with ezabenlimab in advanced and refractory solid tumors.
    Porosnicu M; Quinson AM; Crossley K; Luecke S; Lauer UM
    Future Oncol; 2022 Aug; 18(24):2627-2638. PubMed ID: 35699077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of Oncolytic Viruses in the Treatment of Melanoma.
    Bayan CY; Lopez AT; Gartrell RD; Komatsubara KM; Bogardus M; Rao N; Chen C; Hart TD; Enzler T; Rizk EM; Pradhan JS; Marks DK; Geskin LJ; Saenger YM
    Curr Oncol Rep; 2018 Aug; 20(10):80. PubMed ID: 30145781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virotherapy: From single agents to combinatorial treatments.
    Malfitano AM; Di Somma S; Iannuzzi CA; Pentimalli F; Portella G
    Biochem Pharmacol; 2020 Jul; 177():113986. PubMed ID: 32330494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fusogenic oncolytic vaccinia virus enhances systemic antitumor immune response by modulating the tumor microenvironment.
    Nakatake M; Kuwano N; Kaitsurumaru E; Kurosaki H; Nakamura T
    Mol Ther; 2021 May; 29(5):1782-1793. PubMed ID: 33348052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An engineered oncolytic vaccinia virus encoding a single-chain variable fragment against TIGIT induces effective antitumor immunity and synergizes with PD-1 or LAG-3 blockade.
    Zuo S; Wei M; Xu T; Kong L; He B; Wang S; Wang S; Wu J; Dong J; Wei J
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34949694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade.
    Marchini A; Scott EM; Rommelaere J
    Viruses; 2016 Jan; 8(1):. PubMed ID: 26751469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors.
    Porter CE; Rosewell Shaw A; Jung Y; Yip T; Castro PD; Sandulache VC; Sikora A; Gottschalk S; Ittman MM; Brenner MK; Suzuki M
    Mol Ther; 2020 May; 28(5):1251-1262. PubMed ID: 32145203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncolytic virotherapy, alone or in combination with immune checkpoint inhibitors, for advanced melanoma: A systematic review and meta-analysis.
    Zou P; Tang R; Luo M
    Int Immunopharmacol; 2020 Jan; 78():106050. PubMed ID: 31812724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.